Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A1 | P13866 | 1/20 | 0.40 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 9/20 | 0.39 |
| ▸ | ACACA | Q13085 | 6/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4292194 | 0.91 | MAOB (0.40) | SLC5A1SLC5A2ACACBACACALTA4H | |
| SCHEMBL4285592 | 0.87 | POLB (0.39) | SLC5A1SLC5A2MAOBLMNASMN1; SMN2 | |
| SCHEMBL4285479 | 0.85 | ALDH1A1 (0.36) | MAOBLMNA | |
| SCHEMBL4279556 | 0.85 | POLB (0.39) | ACACBACACAMAOBSMN1; SMN2 | |
| SCHEMBL4292575 | 0.84 | ALDH1A1 (0.37) | SLC5A1SLC5A2MAOBLMNA | |
| SCHEMBL27767699 | 0.84 | NPBWR1 (0.38) | MAOBLMNAL3MBTL1SMN1; SMN2 | |
| SCHEMBL27767693 | 0.82 | PLG (0.37) | SMN1; SMN2 | |
| SCHEMBL4279693 | 0.79 | SLC5A1 (0.45) | SLC5A1SLC5A2ACACBLTA4HMAOB | |
| SCHEMBL4292204 | 0.79 | ALDH1A1 (0.40) | SLC5A1SLC5A2ACACBACACALTA4H | |
| SCHEMBL4284273 | 0.79 | SLC5A1 (0.47) | SLC5A1SLC5A2LTA4HMAOBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101472937-A | Benzylphenylglucopyranoside Derivatives | DAIICHI SANKYO CO LTD (JP) | 2009-07-01 | — | — | CN | disclosed |
| US-20090137499-A1 | BENZYLPHENYL GLUCOPYRANOSIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-2048150-A1 | BENZYL PHENYL GLUCOPYRANOSIDE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2009-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137499-A1 | BENZYLPHENYL GLUCOPYRANOSIDE DERIVATIVE | SLC5A1, SLC5A2, SLC2A1 | SLC5A1 1/4885SLC5A2 2/4885ACACB 1570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.